New genetic and patient analyses suggest severe COVID is linked to overactive complement, one of the immune system’s oldest branches, and excess blood clotting.
New eye drops could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults, a study by Columbia University researchers has found.
Columbia researchers have found hundreds of genes linked to nearsightedness, and now they’re using the data to screen for new drugs that can safeguard sharp vision.
Vagelos student Emery Jamerson’19 received the 2018 Dr. David K. McDonogh Scholarship in Ophthalmology/ENT, named for the first black Columbia-trained doctor in New York.
The most common tests for glaucoma can underestimate the severity of the condition because they do not detect the presence of central vision loss, ophthalmologists at Columbia have found.
The discovery of genes that control eye growth gives researchers critical information in the search for drugs that can prevent nearsightedness, the world’s most common eye disorder.
New genetic findings should help researchers uncover how MacTel, a disease of the retina, develops and how to design therapies to prevent loss of vision.